Recipient of federal assistance · KINGS PARK, NY

CMTX BIOTECH INC

CMTX BIOTECH INC received $1M in federal grants and other assistance in FY2026, on 5 actions, −14% vs FY2025. It has no federal contracts in the loaded years. Since FY2021: $3.6M. Its largest awarding agency was National Institutes of Health ($1M).

Assistance · FY2026
$1M
New awards
3
Actions
5
Since FY2021
$3.6M
UEI
SQJJQU7ZLMB9
Location
KINGS PARK, NY
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 315KFY2021
  2. 0FY2022
  3. 803.5KFY2023
  4. 300KFY2024
  5. 1.2MFY2025
  6. 1MFY2026

By type

  1. Grants$1M100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.837 · Cardiovascular Diseases Research$368K36%
  2. 93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research$349.7K34%
  3. 93.855 · Allergy and Infectious Diseases Research$296.5K29%

Awarding agencies

  1. National Institutes of Health$1M100%
    Department of Health and Human Services

Largest awards

  1. AEROSOLIZED CHEMICALLY MODIFIED TETRACYCLINE NANOFORMULATION FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME - PROJECT…$1.3M
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Nov 30, 2022 – Mar 14, 2026· R42HL166050
  2. A NOVEL, HOST-DIRECTED THERAPEUTIC FOR THE TREATMENT OF SULFUR MUSTARD INDUCED LUNG INJURY - PROJECT SUMMARY/ABSTRACT CMTX BIOTECH IS A…$595.7K
    93.310 · Trans-NIH Research Support· National Institutes of Health· Project grant· Jul 9, 2024 – May 31, 2026· R41AI187083
  3. A LUNG-SPECIFIC, SULFONIUM LIPID NANOPARTICLE (SLNP) FORMULATION OF INCYCLINIDE FOR THE TREATMENT OF ALI/ARDS - PROJECT SUMMARY/ABSTRACT…$368K
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Aug 28, 2026 – Aug 28, 2026· R41HL184801
  4. NOVEL SMALL MOLECULE FOR THE PREVENTION OF HEMORRHAGIC CYSTITIS - PROJECT SUMMARY/ABSTRACT CMTX BIOTECH IS AN EMERGING DRUG DEVELOPMENT…$349.7K
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Jun 23, 2026 – Jun 23, 2026· R41DK143771
  5. DRUG REPURPOSING FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA - PROJECT SUMMARY/ABSTRACT CMTX BIOTECH IS A DRUG DEVELOPMENT…$296.5K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 1, 2026 – Sep 1, 2026· R41AI197642

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.